证券代码：688553 证券简称：汇宇制药 公告编号：2025-084 四川汇宇制药股份有限公司（以下简称"公司"）第二届董事会第二十次会议 于 2025 年 10 月 29 日以通讯表决方式在公司会议室召开。会议通知和会议资料 已于 2025 年 10 月 24 日以电子邮件方式发出，经全体董事一致同意，本次会议 豁免通知期限。本次会议由董事长丁兆先生主持，会议应出席董事 9 人，实际出 席董事 9 人，相关高管列席。本次董事会会议的召集、召开程序符合《中华人民 共和国公司法》等法律法规以及《公司章程》的有关规定，作出的决议合法、有 效。 二、董事会会议审议情况 （一）审议通过《关于公司<2025 年第三季度报告>的议案》 表决结果：9 票同意，0 票反对，0 票弃权。 具体内容详见公司于同日刊登在上海证券交易所网站（www.sse.com.cn） 的《汇宇制药<2025 年第三季度报告>》。 （二）审议通过《关于公司及其关联方共同参与投资私募基金暨关联交易 的议案》 关联董事丁兆回避表决。 四川汇宇制药股份有限公司 董事会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重 ...

Group 1 - The core viewpoint of the news is that Huiyu Pharmaceutical reported a decline in revenue and a net loss for the third quarter of 2025, indicating financial challenges for the company [1] - For the first three quarters of 2025, the company's revenue was approximately 742 million yuan, representing a year-on-year decrease of 12.92% [1] - The net profit attributable to shareholders was a loss of approximately 50.8 million yuan, with basic earnings per share showing a loss of 0.12 yuan [1] Group 2 - As of the report, Huiyu Pharmaceutical's market capitalization stands at 8.7 billion yuan [2] - The broader market context indicates that the A-share market has surpassed 4000 points, marking a significant recovery and a new "slow bull" market pattern [2]

证券代码：688553 证券简称：汇宇制药 公告编号：2025-086 四川汇宇制药股份有限公司 关于使用闲置募集资金进行现金管理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 四川汇宇制药股份有限公司（以下简称"公司"）于 2025 年 10 月 29 日 召开第二届董事会第二十次会议审议通过了《关于公司使用暂时闲置募 集资金进行现金管理的议案》，同意公司在确保不影响募集资金投资计 划正常进行的前提下，使用额度不超过 6 亿元（含本数）的暂时闲置募 集资金进行现金管理，购买安全性高、流动性好、有保本约定的投资产 品（包括但不限于协定存款、通知存款、定期存款、结构性存款、大额 存单、收益凭证等），使用期限自董事会审议通过之日起 12 个月内有效， 在前述额度及使用期限范围内，资金可以循环滚动使用。同时，董事会 授权董事长或董事长授权人士行使现金管理投资决策权并签署相关法 律文件，具体事项由公司财务部负责组织实施。上述事项在公司董事会 审批权限范围内，无需提交公司股东会审批。中信建投证券股份有限公 司（以 ...

证券代码：688553 证券简称：汇宇制药 公告编号：2025-085 四川汇宇制药股份有限公司 关于公司及其关联方共同参与投资私募基金暨 关联交易的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 参与投资私募基金的基本情况：四川汇宇制药股份有限公司（以下简称 "公司"、"汇宇制药"）及其控股股东丁兆先生、原任监事王曙光先生拟与作为 专业投资机构的上海文周投资管理有限公司（以下简称"文周投资"、基金管理 人）合作，参与投资由文周投资作为普通合伙人（GP）、执行事务合伙人的扬州 文周瑞昕创业投资合伙企业（有限合伙）（以下简称"文周瑞昕"、"合伙企业" "私募基金"），文周瑞昕主要对医药行业领域的非上市企业进行投资，与公司主 营业务具有相关性。本合伙企业的资金主要投向南京迈诺威医药科技有限公司。 参与投资金额、在合伙企业中的占比及身份：汇宇制药拟作为文周瑞昕 的有限合伙人（LP）以自有资金认缴出资人民币 700 万元；汇宇制药实际控制 人、控股股东丁兆先生拟作为文周瑞昕的有限合伙人（LP）以自有资金认缴出 资 ...

Financial Performance - The company's operating revenue for Q3 2025 was ¥288,631,567.14, a decrease of 9.70% compared to the same period last year[4] - The total profit for the period was ¥28,720,387.90, reflecting a significant decline of 83.93% year-over-year[4] - The net profit attributable to shareholders was ¥29,915,841.81, down 81.55% from the previous year[4] - The basic earnings per share for the current period was ¥0.07, a decrease of 81.58% year-over-year[4] - The net profit excluding non-recurring gains and losses for the current period was ¥31,487,449.01, a decrease of 44.89% year-over-year[4] - Total operating revenue for the first three quarters of 2025 was CNY 741.75 million, a decrease of 12.93% compared to CNY 851.84 million in the same period of 2024[19] - Net profit for the first three quarters of 2025 was a loss of CNY 55.07 million, compared to a profit of CNY 220.77 million in the same period of 2024[20] - The company reported a significant decrease in net profit attributable to shareholders, which was a loss of CNY 50.80 million in 2025 compared to a profit of CNY 227.35 million in 2024[20] - The comprehensive income attributable to the parent company's owners for the first three quarters of 2025 was -52,916,564.33 RMB, compared to 229,304,833.45 RMB in the same period of 2024, indicating a significant decline[21] - Basic and diluted earnings per share for the first three quarters of 2025 were both -0.12 RMB, down from 0.54 RMB in the same period of 2024[21] Expenses and Costs - Research and development expenses totaled ¥94,910,464.56, an increase of 28.33% compared to the same quarter last year, representing 32.88% of operating revenue[4] - Total operating costs for the first three quarters of 2025 were CNY 685.55 million, down 7.56% from CNY 741.47 million in 2024[19] - The company is focusing on cost control measures, as evidenced by a reduction in sales expenses from CNY 326.66 million in 2024 to CNY 272.03 million in 2025[19] Assets and Liabilities - The total assets at the end of the reporting period were ¥4,876,237,650.64, a decrease of 5.60% from the end of the previous year[5] - Total assets decreased to CNY 4.88 billion in 2025 from CNY 5.17 billion in 2024, indicating a contraction in the company's asset base[16] - Total liabilities decreased to CNY 1.16 billion in 2025 from CNY 1.19 billion in 2024, showing a reduction in financial obligations[16] Cash Flow - The net cash flow from operating activities for the year-to-date was ¥31,168,333.28, down 80.79% compared to the same period last year[4] - Net cash flow from operating activities for the first three quarters of 2025 was 31,168,333.28 RMB, a decrease of 80.8% compared to 162,244,732.53 RMB in the same period of 2024[22] - Cash inflow from operating activities totaled 1,031,888,173.09 RMB, slightly down from 1,038,292,103.01 RMB in the previous year[22] - Cash outflow from operating activities increased to 1,000,719,839.81 RMB, compared to 876,047,370.48 RMB in the same period of 2024[22] - Cash flow from investing activities generated a net inflow of 138,140,039.42 RMB, compared to 134,415,817.02 RMB in the same period of 2024[23] - Cash inflow from investing activities was 583,495,601.60 RMB, down from 1,198,249,243.58 RMB in the previous year[23] - Cash flow from financing activities resulted in a net outflow of -100,519,702.26 RMB, contrasting with a net inflow of 33,105,508.60 RMB in the same period of 2024[23] - The ending balance of cash and cash equivalents as of September 2025 was 2,129,942,698.64 RMB, an increase from 1,959,830,216.33 RMB at the end of September 2024[23] Shareholder Information - Total number of common shareholders at the end of the reporting period is 13,908[12] - The largest shareholder, Ding Zhao, holds 114,066,766 shares, representing 26.93% of total shares[12] - The number of shares held by the top ten shareholders includes significant holdings by Huang Qianyi (27,219,439 shares, 6.43%) and Wang Xiaopeng (17,037,557 shares, 4.02%)[12] - The total number of shares held by shareholders with frozen shares includes 27,219,439 shares held by Huang Qianyi[12] - The company has not reported any changes in the participation of major shareholders in margin trading activities[14] - The company has not received any declarations regarding related party relationships among shareholders[14] Market Outlook - The company anticipates continued challenges in the market, which may affect future performance and strategic initiatives[20] Accounting Standards - The company did not apply new accounting standards or interpretations starting in 2025[24]

Group 1 - The core point of the article is that Huiyu Pharmaceutical reported a decline in both revenue and net profit for the third quarter and the first three quarters of the year [1] Group 2 - For the third quarter, the company's revenue was 289 million yuan, a year-on-year decrease of 9.70% [1] - The net profit for the third quarter was 29.92 million yuan, reflecting a significant year-on-year decline of 81.55% [1] - For the first three quarters, the total revenue was 742 million yuan, which represents a year-on-year decrease of 12.92% [1] - The net profit for the first three quarters was -50.80 million yuan, indicating a year-on-year decline of 122.35% [1]

证券代码：688553 证券简称：汇宇制药 公告编号：2025-083 四川汇宇制药股份有限公司 关于自愿披露公司参与全国药品集中采购拟中选的公告 本次公司拟中选的产品于 2024 年 10 月获得国家药品监督管理局签发的《药 品注册证书》，本次中标前暂未产生销售收入。 本次集中采购是国家组织的第十一批药品集中带量采购，采购周期中，医疗 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 四川汇宇制药股份有限公司（以下简称"公司"）全资子公司四川汇宇海玥 医药科技有限公司参与了国家组织药品联合采购办公室（以下简称"联采办"） 组织的第十一批全国药品集中采购的投标工作，根据联采办于 2025 年 10 月 28 日在上海阳光医药采购网（https://www.smpaa.cn）发布的《全国药品集中采购拟 中选结果公示》显示，公司 1 个产品拟中标本次集中采购，现将相关情况公告如 下： | 序 | 拟中选 | 适应症 | 包装 | 计价 | 拟中选 | 采购周期 | | | --- | --- | --- | --- | --- ...

Core Viewpoint - The company, Huilong Pharmaceutical, announced its subsidiary's participation in the 11th national centralized drug procurement organized by the National Drug Procurement Office, with one product, Meisobam Injection, expected to win the bid [1] Group 1 - The company’s subsidiary, Sichuan Huilong Haiyue Pharmaceutical Technology Co., Ltd., is involved in the bidding process for centralized drug procurement [1] - The product Meisobam Injection is anticipated to be awarded in this procurement round [1] - The product is expected to receive its drug registration certificate from the National Medical Products Administration in October 2024, and has not generated any sales revenue prior to this bid [1]

Core Points - The stock of Huayu Pharmaceutical (688553.SH) closed at 21.28 yuan, reflecting a decline of 2.96% and is currently in a state of breaking below its initial public offering price [1] - Huayu Pharmaceutical was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on October 26, 2021, with an initial public offering of 63.6 million shares at a price of 38.87 yuan per share [1] - On the first day of trading, the stock reached a peak of 42.59 yuan, marking the highest price since its listing [1] - The total funds raised from the IPO amounted to 2.472 billion yuan, with a net amount of 2.361 billion yuan after deducting issuance costs, which was 453 million yuan more than the original plan [1] - The company intended to raise 1.907 billion yuan for projects including the construction of a second phase of the EU-standard injection production base and the establishment of an innovative drug research institute, as well as to supplement working capital [1] - The total issuance costs were 111 million yuan, with underwriting fees to CITIC Securities and Guodu Securities amounting to 98.875 million yuan [1]

Core Points - Huiyu Pharmaceutical (688553.SH) closed at 21.28 yuan, with a decline of 2.96%, currently in a state of breaking issue [1] - The company was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on October 26, 2021, with an initial public offering (IPO) of 63.6 million shares at a price of 38.87 yuan per share [1] - On the first day of trading, the stock reached a peak of 42.59 yuan, marking the highest price since its listing [1] Fundraising and Financials - Huiyu Pharmaceutical raised a total of 2.472 billion yuan through the IPO, with a net amount of 2.361 billion yuan after deducting issuance costs [1] - The net fundraising amount exceeded the original plan by 453 million yuan [1] - The company intended to use the funds for the construction of the EU-standard injection production base (Phase II), the establishment of an innovative drug research institute, and to supplement working capital [1] - Total issuance costs amounted to 111 million yuan, with underwriting fees to CITIC Securities and Guodu Securities totaling 98.875 million yuan [1]